FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4250400830> ?p ?o ?g. }

• W4250400830 endingPage "389" @default.
• W4250400830 startingPage "381" @default.
• W4250400830 abstract "A group of patients with cystic fibrosis (CF) have severe small airways disease characterized by wheeze, chest tightness and limited sputum production, often with deteriorating lung function. Suggested mechanisms include mucosal edema secondary to infection and inflammation, smooth muscle contraction caused by inflammatory mediators, and collapse of bronchiectatic airways. While treatment with long-term oral corticosteroids may result in symptomatic improvement, adverse effects often make them intolerable. Inhaled corticosteroids are used in many centers despite the lack of conclusive evidence of their efficacy. Therapeutic alternatives to corticosteroids are aimed at reversing bronchoconstriction and reducing inflammation. Many patients with CF are treated with short- and long-term inhaled bronchodilators, but data to support their use are inconclusive. Other attempted routes of administration for short-acting bronchodilators include the subcutaneous and intravenous routes, but clinical data are again lacking. Sodium cromoglycate (cromolyn sodium) has been studied, with little evidence of benefit. Theophyllines have also been studied, both intravenously and orally, with some effect, but are not often used in clinical practice. Nonsteroidal anti-inflammatory therapies include ibuprofen, macrolide antibiotics, intravenous immunoglobulin, cyclosporine, and leukotriene antagonists. Ibuprofen has been shown to be useful in patients with mild CF disease, but concerns about potential adverse effects have limited its use. The results of various macrolide studies are awaited, but to date there are no long-term studies published. While there is great interest in the potential of intravenous immunoglobulin, cyclosporine and leukotriene antagonists, the evidence for their effectiveness comes from anecdotal reports, thus there is currently insufficient data to support their use. Since this is a small group of patients, it is unlikely that sufficient numbers will ever be recruited for these studies; thus it is probable that drugs will be tried on an individual patient basis. The order in which they are attempted is unclear, but it would be sensible to try the least invasive medication with the least adverse effects first, moving on to more potent, but more toxic drugs if that treatment fails." @default.
• W4250400830 created "2022-05-12" @default.
• W4250400830 creator A5054590049 @default.
• W4250400830 creator A5055346025 @default.
• W4250400830 date "2002-01-01" @default.
• W4250400830 modified "2023-10-18" @default.
• W4250400830 title "Treatment of Severe Small Airways Disease in Children with Cystic Fibrosis" @default.
• W4250400830 doi "https://doi.org/10.2165/00148581-200204060-00005" @default.
• W4250400830 hasPublicationYear "2002" @default.
• W4250400830 type Work @default.
• W4250400830 citedByCount "1" @default.
• W4250400830 countsByYear W42504008302021 @default.
• W4250400830 crossrefType "journal-article" @default.
• W4250400830 hasAuthorship W4250400830A5054590049 @default.
• W4250400830 hasAuthorship W4250400830A5055346025 @default.
• W4250400830 hasBestOaLocation W42504008301 @default.
• W4250400830 hasConcept C126322002 @default.
• W4250400830 hasConcept C177713679 @default.
• W4250400830 hasConcept C197934379 @default.
• W4250400830 hasConcept C203014093 @default.
• W4250400830 hasConcept C2776042228 @default.
• W4250400830 hasConcept C2776322731 @default.
• W4250400830 hasConcept C2776938444 @default.
• W4250400830 hasConcept C2778338976 @default.
• W4250400830 hasConcept C2779944601 @default.
• W4250400830 hasConcept C71924100 @default.
• W4250400830 hasConcept C98274493 @default.
• W4250400830 hasConceptScore W4250400830C126322002 @default.
• W4250400830 hasConceptScore W4250400830C177713679 @default.
• W4250400830 hasConceptScore W4250400830C197934379 @default.
• W4250400830 hasConceptScore W4250400830C203014093 @default.
• W4250400830 hasConceptScore W4250400830C2776042228 @default.
• W4250400830 hasConceptScore W4250400830C2776322731 @default.
• W4250400830 hasConceptScore W4250400830C2776938444 @default.
• W4250400830 hasConceptScore W4250400830C2778338976 @default.
• W4250400830 hasConceptScore W4250400830C2779944601 @default.
• W4250400830 hasConceptScore W4250400830C71924100 @default.
• W4250400830 hasConceptScore W4250400830C98274493 @default.
• W4250400830 hasIssue "6" @default.
• W4250400830 hasLocation W42504008301 @default.
• W4250400830 hasOpenAccess W4250400830 @default.
• W4250400830 hasPrimaryLocation W42504008301 @default.
• W4250400830 hasRelatedWork W1954408922 @default.
• W4250400830 hasRelatedWork W1978689032 @default.
• W4250400830 hasRelatedWork W1983034461 @default.
• W4250400830 hasRelatedWork W199933018 @default.
• W4250400830 hasRelatedWork W205180216 @default.
• W4250400830 hasRelatedWork W2118319650 @default.
• W4250400830 hasRelatedWork W2128878787 @default.
• W4250400830 hasRelatedWork W1559996047 @default.
• W4250400830 hasRelatedWork W2189013337 @default.
• W4250400830 hasRelatedWork W2798972099 @default.
• W4250400830 hasVolume "4" @default.
• W4250400830 isParatext "false" @default.
• W4250400830 isRetracted "false" @default.
• W4250400830 workType "article" @default.